Figure 4: Micrograph of Hippocampus (CA2) of Wistar rats (H and E, × 250). (a) Control (distilled water 2 ml/kg) group with normal histoarchitecture of the pyramidal cells (P). (b) Lead acetate (120 mg/kg) treated group with distortions in the histoarchitecture of the cells such as karyorrhexis (K) and gliosis (g). (c) Lead acetate (120 mg/kg) and Ascorbic acid (100 mg/kg) treated group with mild distortions in the histoarchitecture of the hippocampus. pyramidal cells (P), cV and gliosis (g). (d) Lead acetate (120 mg/kg) and EECL (375 mg/kg) treated group with mild distortions in the histoarchitecture of the hippocampus. Gliosis (g), cV and some restoration of the histoarchitecture of the pyramidal cells (P). (e) Lead acetate (120 mg/kg) and EECL (750 mg/kg) treated group with some improvement in the histoarchitecture of the hippocampus. Karyorrhexis (k) and gliosis (g). (f) Lead acetate (120 mg/kg) and EECL (1500 mg/kg) treated group with marked improvement in the histoarchitecture of the hippocampus cV. cV: Cytoplasmic vacuolation